DDInter1031 DDInter200
Ledipasvir is a direct acting antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as ledipasvir. More specifically, ledipasvir is an inhibitor of the Hepatitis C Virus (HCV) Non-Structural Protein 5A (NS5A), which is required for viral RNA replication and assembly of HCV virions. Although its exact mechanism of action is unknown, it is postulated to prevent hyperphosphorylation of NS5A which is required
Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals Inc., is prescribed as a venous thromboembolism (VTE) prophylactic for adult patients with moderate to severe restricted motility or with other risks for VTE . VTE can be manifested as deep vein thrombosis or pulmonary embolism and it is a leading cause of preventable death in hospitalized patients .
Betrixaban {u} may cause a minor interaction that can limit clinical effects when taken with {v} Clove
Betrixaban {u} may cause a minor interaction that can limit clinical effects when taken with {v} Turmeric
Betrixaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Amprenavir
Betrixaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Berotralstat
Betrixaban {u} may lead to a major life threatening interaction when taken with {v} Iloprost
Betrixaban {u} may lead to a major life threatening interaction when taken with {v} Avapritinib
Betrixaban may cause a minor interaction that can limit clinical effects when taken with Clove
Betrixaban may cause a minor interaction that can limit clinical effects when taken with Turmeric
Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Amprenavir
Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Berotralstat
Betrixaban may lead to a major life threatening interaction when taken with Iloprost
Betrixaban may lead to a major life threatening interaction when taken with Avapritinib